29 March 2018, Liverpool, UK – EnXray Ltd, a sterilisation technology company, today confirmed Team EnXray has delivered the 3rd Key Milestone ahead of the deadline (31st March).
Robert Barlow, CEO of EnXray, said: "This moves EnXray towards generating our first functional specification, allowing the business to move into the Prototype phase".
Notes to editors
About EnXray Limited EnXray Limited (EnXray) is a development-stage technology company founded in 2012, focused on commercializing its proprietary Low Energy X-rays (LEXR) technology for use in sterilization. EnXray’s first target market is the medical device manufacturing industry, where our technology will enable companies to manage and control the sterilization of their products (the final critical step of their production process) on-site & on-demand, providing significant benefits to its customers.
LEXR, or “soft x-rays” are a form of ionizing radiation in the range of 5 – 20 keV, which have some compelling characteristics, including a short transmission range through air, combined with a high absorption coefficient, which makes it a very efficient method for delivering high dosages of radiation in a relatively short period of time, without the need for extensive shielding. This is different from gamma-irradiation, where products have to be paletted in order to get reasonable sterilization efficacy, LEXR is designed for end-of-line processing and sterilization of individual products.